Seizure classification using a multimodal seizure monitoring system (Nelli) in Dravet and Lennox–Gastaut syndromes: A non‐randomized, single‐center feasibility study
Epilepsia · 2026
DOI: 10.1111/epi.18640 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia, 2026. Verfasst von Line Kønig Wilms und 6 weiteren Autor:innen. Beteiligte Einrichtung: Filadelfia Hospital, Dianalund, Denmark. Hauptthemen laut MEDLINE: Lennox Gastaut Syndrome, Epilepsies, Myoclonic, Seizures. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Takeda Pharma AB.
Abstract (Originalsprache)
Objective
This study aimed to assess the performance of the Nelli seizure monitoring system in detecting and classifying seizures during sleep or while at rest in bed in patients with Lennox–Gastaut syndrome (LGS) and Dravet syndrome (DS).
Methods
We conducted a non‐interventional, single‐center feasibility study from August 2023 to March 2024, involving 20 patients aged ≥2 years diagnosed with DS or LGS. Participants used Nelli for home‐based seizure monitoring during sleep or while at rest in bed for 4 weeks. Seizures were detected and classified by Nelli, and results were compared to epileptologist reviews and seizure diaries.
Results
Of 20 enrolled patients, 14 (70%) who experienced seizures at rest were included in the analyses. Among them, Nelli detected 368 seizures, with an accuracy of 97.8%, as confirmed by independent reviewers. Eight seizures (2.2%) detected by Nelli were false positives, identified as part of a single seizure episode. Of the 14 patients, only 35.7% reported experiencing seizures in their diaries, and only 26.1% of the seizures were documented. Seizure durations ranged from 6 to 396 s, with considerable variation. Nelli demonstrated high accuracy in seizure classification (Gwet agreement coefficient [AC1] = .81–1.00) in nine of 14 cases. However, in three of 14 patients, moderate accuracy (AC1 = .41–.60) was observed due to challenges in classifying seizures in patients with high seizure frequency or suboptimal device positioning. The average classification accuracy of Nelli for tonic–clonic seizures was .99 (150/152 seizures), tonic seizures .55 (102/186), clonic seizures 1.00 (3/3), focal motor seizures .89 (16/18), and myoclonic seizures 1.00 (1/1). Significance Nelli demonstrated high sensitivity and classification accuracy for detecting and categorizing seizures in bed in patients with DS and LGS, outperforming seizure diaries and providing a reliable tool for seizure monitoring in home settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Filadelfia Hospital, Dianalund, Denmark.
- National Center for Epilepsy, full member of European Reference Network EpiCARE, University of Oslo, Oslo, Norway.
- Neuro Event Labs, Tampere, Finland.
- Takeda Pharma A/S, Vallensbæk, Denmark.
- Takeda Pharma Vertrieb, Berlin, Germany.
- Takeda, Helsinki, Finland.
ORCID-Profile: Line Kønig Wilms, Morten I Lossius, Kaapo Annala, Jonas Abdel-Khalik, Lena Fanter, Kaisa Elomaa, Jukka Peltola
Förderung
- Takeda Pharma AB
Zitieren
APA
Wilms, L. K., Lossius, M. I., Annala, K., Abdel-Khalik, J., Fanter, L., Elomaa, K., & Peltola, J. (2026). Seizure classification using a multimodal seizure monitoring system (Nelli) in Dravet and Lennox–Gastaut syndromes: A non‐randomized, single‐center feasibility study. Epilepsia. https://doi.org/10.1111/epi.18640
Vancouver
Wilms LK, Lossius MI, Annala K, Abdel-Khalik J, Fanter L, Elomaa K, et al. Seizure classification using a multimodal seizure monitoring system (Nelli) in Dravet and Lennox–Gastaut syndromes: A non‐randomized, single‐center feasibility study. Epilepsia. 2026. doi:10.1111/epi.18640
BibTeX
@article{Wilms2026,
author = {Wilms, Line Kønig and Lossius, Morten I and Annala, Kaapo and Abdel-Khalik, Jonas and Fanter, Lena and Elomaa, Kaisa and Peltola, Jukka},
title = {Seizure classification using a multimodal seizure monitoring system (Nelli) in Dravet and Lennox–Gastaut syndromes: A non‐randomized, single‐center feasibility study},
journal = {Epilepsia},
year = {2026},
doi = {10.1111/epi.18640}
}
EUVIMED